Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Protein Degradation, Gene Therapy Enhancement, and Immunosuppression Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FKBP1A (FKBP12) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FKBP1A WT / Mutant Protein (F36V). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified by Mass Spec. E. coli / HEK293 Expressed. | View FKBP1A Products |
| Gene Delivery | FKBP1A Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. | View FKBP1A Products |
| Benchmark Ab | Anti-FKBP1A Reference Antibody (Polyclonal). Recombinant positive control for Western and ELISA. | View FKBP1A Products |
| Validator | FKBP1A siRNA Set. For knockdown verification and specificity controls. | View FKBP1A Products |
| Related Target A | MTOR. Forms ternary complex with FKBP1A and rapamycin for pathway inhibition. | View MTOR Products |
| Related Target B | CRBN. Synergistic target for PROTAC and molecular glue degrader panels. | View CRBN Products |
| Related Target C | FKBP1B (FKBP12.6). Cardiac-selective paralog for selectivity profiling and off-target screening. | View FKBP1B Products |
| Related Target D | PPP3CA (Calcineurin A). Functional binding partner for ternary complex assays (FK506 mechanism). | View PPP3CA Products |
| Related Target E | AAVR (KIAA0319L). AAV5 co-receptor for gene therapy mechanism studies. | View AAVR Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Validation (SPR/BLI) | High purity (>95%) recombinant FKBP1A, strictly verified by mass spectrometry for precise MW. Low endotoxin (<1 EU/µg) for sensitive assays. |
| dTAG / Orthogonal System Screening | Mutant proteins (e.g., F36V) available to support targeted degradation selectivity assays. |
| PPIase Enzymatic Activity (Catalytic efficiency) | High-purity (>95%) recombinant protein with native folding verified by CD spectroscopy; suitable for chymotrypsin-coupled assay. |
| Molecular Glue Ternary Complex Formation | Tag-free format available for ITC/SPR. Low endotoxin for cell-based PPI assays. |
| Paralog Selectivity (FKBP1B vs FKBP1A) | Human FKBP1B ortholog protein available with strict mass spec verification for counter-screening. |
| AAV5 Transduction Mechanism | Cell-based assay enabled by FKBP1A lentivirus particles for stable overexpression. |
| Lack of Reliable Controls | Sequence-verified recombinant benchmark antibodies included. |
| False Positives in Knockdown | Validated siRNA set for strict specificity checks in cellular assays. |
| Compound Binding Affinity (Rapamycin site) | F36V mutant protein (rapamycin-binding deficient) for mechanistic studies. |
Live FKBP1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research & Molecular Glue Research
- ➤ AAV5 Gene Therapy Mechanism
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The FKBP1A target landscape is experiencing a paradigm shift from traditional calcineurin inhibition (tacrolimus/FK506) toward next-generation modalities. Major players are shifting focus from traditional small molecule immunosuppressants to Molecular Glues, PROTACs, and orthogonal degradation systems (like dTAG) for CAR-T cell switch control and novel bi-functional molecules. Concurrently, FKBP1A has emerged as a critical host factor for AAV5 viral entry, opening new avenues for gene therapy enhancement. As first-generation immunosuppressants face toxicity limitations, the next wave of R&D targets selective PPIase inhibition, ternary complex formation for targeted protein degradation, and AAV5 transduction efficiency modulation. Pristine reagents (high-purity WT and mutant proteins) are essential for precise biophysical characterization and mechanism-of-action studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (PPIase) | Academic consortia, Autoimmune biotechs | Rheumatoid Arthritis, Transplant rejection | Enzymatic activity assay (Need high-specific-activity WT protein) |
| Molecular Glues / PROTACs | Arvinas, Kymera, Novartis, Bio-techs | Oncology, Neurodegeneration | Ternary Complex SPR Assay (Need high-purity WT FKBP1A) |
| dTAG Modulators (Cell Therapy) | C4 Therapeutics, Dana-Farber | Next-Gen CAR-T Control | Selectivity Assay (Need F36V Mutant vs WT Proteins) |
| Gene Therapy Adjuncts | AAV vector developers | Inherited retinal diseases, Hemophilia | AAV5 Transduction Assay (Need stable FKBP1A-overexpressing cell lines) |
| Rapamycin Analogs (mTOR) | Rapalog specialty pharma | Aging, Metabolic disease | FRB Domain Competition Assay (Need FRB-FKBP1A binding validation) |
Molecular Differentiation & Assay Strategy
Successful FKBP1A-targeted drug discovery requires careful consideration of affinity/kinetics, selectivity, and ternary complex stability. Affinity & Kinetics: Molecular glues typically need moderate affinity (μM) for reversibility, while immunosuppressants require high affinity (nM). SPR or ITC with tag-free, high-purity (>95%) FKBP1A is recommended. Paralog Selectivity: FKBP1B shares 84% homology; >100-fold selectivity is needed to avoid cardiac toxicity. Parallel screening with human FKBP1A and FKBP1B orthologs using DSF or competitive binding is essential. Ternary Complex Stability: For degraders, the half-life of the FKBP1A-glue-POI complex determines efficacy. Use full-length active PPP3CA or custom POI in pull-down/AlphaLISA assays. AAV5 Functional Validation: Stable cell lines overexpressing WT vs F36V mutant FKBP1A serve as functional controls to distinguish PPIase-dependent and independent entry mechanisms. TarMart provides all required reagents (WT/mutant proteins, lentivirus, siRNA, antibodies) with rigorous quality control (mass spec, CD spectroscopy, low endotoxin) to support these assays.